Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, et al. Towards patient-based cancer therapeutics. Nat Biotechnol. 2010;28(9):904-6. doi:10.1038/nbt0910-904
Levin JZ, Berger MF, Adiconis X, et al. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol. 2009;10(10):R115. doi:10.1186/gb-2009-10-10-r115
Chandra S, Muir C, Silva M, Carr S. Imaging biomarkers in drug development: an overview of opportunities and open issues. J Proteome Res. 2005;4(4):1134-7. doi:10.1021/pr0500915
Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2(1):82-93. doi:10.1158/2159-8290.CD-11-0184
Hagerstrand D, Tong A, Schumacher SE, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57. doi:10.1158/2159-8290.CD-12-0592
Mihaylova MM, Sabatini DM, Yilmaz Ömer H. Dietary and metabolic control of stem cell function in physiology and cancer. Cell Stem Cell. 2014;14(3):292-305. doi:10.1016/j.stem.2014.02.008
Streit M, Lex A, Gratzl S, et al. Guided visual exploration of genomic stratifications in cancer. Nat Methods. 2014;11(9):884-5. doi:10.1038/nmeth.3088
Abbatiello SE, Schilling B, Mani DR, et al. Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics. 2015;14(9):2357-74. doi:10.1074/mcp.M114.047050
Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. Science. 2015;350(6257):211-7. doi:10.1126/science.aaa4903
Haradhvala NJ, Polak P, Stojanov P, et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell. 2016;164(3):538-49. doi:10.1016/j.cell.2015.12.050